Rhelion Life Sciences Corp. TRUFF
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -21.28% | -30.15% | -37.64% | -41.20% | -24.91% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -21.28% | -30.15% | -37.64% | -41.20% | -24.91% |
| Cost of Revenue | -28.91% | -28.88% | -32.26% | -37.19% | -18.50% |
| Gross Profit | -8.01% | -32.16% | -46.03% | -47.09% | -33.93% |
| SG&A Expenses | 6.69% | -6.56% | -22.24% | -29.38% | -29.55% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | 100.00% | 100.00% | -- |
| Total Operating Expenses | -1.17% | -12.33% | -24.30% | -30.86% | -28.07% |
| Operating Income | -18.56% | -8.68% | 9.64% | 19.98% | 30.93% |
| Income Before Tax | -77.68% | -67.43% | 14.74% | 27.02% | 41.13% |
| Income Tax Expenses | -130.83% | -214.89% | -581.77% | -378.46% | -217.88% |
| Earnings from Continuing Operations | -75.98% | -63.84% | 17.09% | 29.08% | 42.62% |
| Earnings from Discontinued Operations | -428.96% | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 201.83% | 188.23% | 102.03% | 156.29% | 117.35% |
| Net Income | -83.41% | -52.82% | 21.20% | 33.58% | 46.85% |
| EBIT | -18.56% | -8.68% | 9.64% | 19.98% | 30.93% |
| EBITDA | -30.84% | -21.75% | -0.97% | 15.56% | 31.52% |
| EPS Basic | -67.16% | -47.22% | 23.01% | 35.00% | 48.46% |
| Normalized Basic EPS | 2.86% | 5.41% | 14.29% | 27.78% | 41.67% |
| EPS Diluted | -67.16% | -47.22% | 23.01% | 35.00% | 48.46% |
| Normalized Diluted EPS | 2.86% | 5.41% | 14.29% | 27.78% | 41.67% |
| Average Basic Shares Outstanding | 11.59% | 3.86% | 3.17% | 2.54% | 2.05% |
| Average Diluted Shares Outstanding | 11.59% | 3.86% | 3.17% | 2.54% | 2.05% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |